Rectal Cancer

Oncology
21
Pipeline Programs
18
Companies
23
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
14
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
583%
Vaccine
117%
+ 21 programs with unclassified modality

Competitive Landscape

17 companies ranked by most advanced pipeline stage

Rocket Pharmaceuticals
3 programs
1
SIS-reinforced anastomosisPhase 41 trial
Clostridium butyricumN/A1 trial
Delayed transanal pull-through anastomosisN/A1 trial
Active Trials
NCT07369830Recruiting156Est. Jun 2029
NCT06662643Active Not Recruiting110Est. Dec 2029
NCT07209787Recruiting966Est. Aug 2027
Roche
RocheSTAVANGER NORWAY, Norway
3 programs
2
1
Folinic Acid, interferon-alphaPhase 31 trial
Bevacizumab + Capecitabine + RadiotherapyPhase 21 trial
Capecitabine, Oxaliplatin and CetuximabPhase 2Monoclonal Antibody
Active Trials
NCT01043484Completed90Est. Aug 2016
NCT01060501Completed796Est. Jul 2009
M&
Merck & Co.RAHWAY, NJ
1 program
1
Tegafur and UracilPhase 31 trial
Active Trials
NCT00207831Terminated219Est. Feb 2008
Providence Therapeutics
2 programs
1
TAS 102Phase 2
Patient Activation Booklet and nursing support for patients with LARSN/A1 trial
Active Trials
NCT03828318CompletedEst. Jan 2024
Genentech
GenentechCA - Oceanside
2 programs
1
1
AvastinPhase 21 trial
BevacizumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT00543842Completed19Est. Dec 2013
NCT00113230Completed25Est. Jan 2009
CT
2 programs
1
1
Short-course radiotherapyPhase 21 trial
Bevacizumab injectionPhase 11 trial
Active Trials
NCT05476341CompletedEst. Aug 2017
NCT05576480RecruitingEst. Dec 2026
Bristol Myers Squibb
2 programs
2
CetuximabPhase 2Monoclonal Antibody1 trial
FOLFOX4Phase 2
Active Trials
NCT00611858Terminated13Est. Sep 2016
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
2
CetuximabPhase 2Monoclonal Antibody1 trial
FOLFOX4Phase 21 trial
Active Trials
NCT00527111Completed139Est. Jan 2015
NCT00580073Terminated6Est. Nov 2009
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
2
PanitumumabPhase 2Monoclonal Antibody1 trial
protective ileostomyPhase 21 trial
Active Trials
NCT01443377Completed48Est. Sep 2013
NCT00457327Terminated40Est. Mar 2007
Arcus Biosciences
1 program
1
EtrumadenantPhase 21 trial
Active Trials
NCT05024097RecruitingEst. Dec 2030
Sanofi
SanofiPARIS, France
1 program
1
FOLFOX4Phase 2
Taiho Oncology
Taiho OncologyNJ - Princeton
1 program
1
TAS 102Phase 21 trial
Active Trials
NCT04417699CompletedEst. Feb 2024
Design Therapeutics
1 program
1
CEA protein antigen plus BCG Vaccine Mix for percutaneous usePhase 1Vaccine1 trial
Active Trials
NCT02403505Active Not RecruitingEst. Feb 2026
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
FOLFOX-4Phase 11 trial
Active Trials
NCT00101894Completed119Est. Dec 2011
Bayer
BayerLEVERKUSEN, Germany
1 program
MR-PETN/A1 trial
Active Trials
NCT02651701Completed71Est. Nov 2019
Varian Medical Systems
1 program
Maastro applicatorN/A1 trial
Active Trials
NCT06087718Active Not RecruitingEst. Apr 2031
Genomics
GenomicsUK - Oxford
1 program
ctDNAN/A1 trial
Active Trials
NCT05629442Not Yet Recruiting60Est. Jun 2030

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Rocket PharmaceuticalsSIS-reinforced anastomosis
Merck & Co.Tegafur and Uracil
RocheFolinic Acid, interferon-alpha
Chia Tai TianQing Pharmaceutical GroupShort-course radiotherapy
Taiho OncologyTAS 102
Arcus BiosciencesEtrumadenant
Heidelberg PharmaPanitumumab
RocheBevacizumab + Capecitabine + Radiotherapy
Bristol Myers SquibbCetuximab
Eli Lilly and CompanyFOLFOX4
Eli Lilly and CompanyCetuximab
Heidelberg Pharmaprotective ileostomy
GenentechAvastin
Design TherapeuticsCEA protein antigen plus BCG Vaccine Mix for percutaneous use
Chia Tai TianQing Pharmaceutical GroupBevacizumab injection

Showing 15 of 23 trials with date data

Clinical Trials (23)

Total enrollment: 2,877 patients across 23 trials

NCT07209787Rocket PharmaceuticalsSIS-reinforced anastomosis

SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak

Start: Sep 2025Est. completion: Aug 2027966 patients
Phase 4Recruiting
NCT00207831Merck & Co.Tegafur and Uracil

Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma

Start: Jul 2004Est. completion: Feb 2008219 patients
Phase 3Terminated
NCT01060501RocheFolinic Acid, interferon-alpha

Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon Cancer

Start: Jul 1992Est. completion: Jul 2009796 patients
Phase 3Completed
NCT05576480Chia Tai TianQing Pharmaceutical GroupShort-course radiotherapy

SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer

Start: Feb 2023Est. completion: Dec 2026
Phase 2Recruiting
NCT04417699Taiho OncologyTAS 102

SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer

Start: Jul 2022Est. completion: Feb 2024
Phase 2Completed
NCT05024097Arcus BiosciencesEtrumadenant

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

Start: Mar 2022Est. completion: Dec 2030
Phase 2Recruiting
NCT01443377Heidelberg PharmaPanitumumab

Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer

Start: Jul 2011Est. completion: Sep 201348 patients
Phase 2Completed
NCT01043484RocheBevacizumab + Capecitabine + Radiotherapy

Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer

Start: Dec 2009Est. completion: Aug 201690 patients
Phase 2Completed
NCT00611858Bristol Myers SquibbCetuximab

Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

Start: May 2008Est. completion: Sep 201613 patients
Phase 2Terminated
NCT00580073Eli Lilly and CompanyFOLFOX4

Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum

Start: Dec 2007Est. completion: Nov 20096 patients
Phase 2Terminated
NCT00527111Eli Lilly and CompanyCetuximab

Pre-op Rectal ChemoRad +/- Cetuximab

Start: Feb 2007Est. completion: Jan 2015139 patients
Phase 2Completed
NCT00457327Heidelberg Pharmaprotective ileostomy

Pilot Study for Evaluation of the Need for Protective Ileostomy After Low Anterior Resection Due to Rectal Cancer

Start: Jul 2006Est. completion: Mar 200740 patients
Phase 2Terminated
NCT00113230GenentechAvastin

Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer

Start: Feb 2005Est. completion: Jan 200925 patients
Phase 2Completed
NCT02403505Design TherapeuticsCEA protein antigen plus BCG Vaccine Mix for percutaneous use

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer

Start: Dec 2021Est. completion: Feb 2026
Phase 1Active Not Recruiting
NCT05476341Chia Tai TianQing Pharmaceutical GroupBevacizumab injection

A Phase I Clinical Trial of Bevacizumab Injection

Start: Apr 2017Est. completion: Aug 2017
Phase 1Completed
NCT00543842GenentechBevacizumab

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

Start: Dec 2007Est. completion: Dec 201319 patients
Phase 1Completed
NCT00101894AmgenFOLFOX-4

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Start: Dec 2004Est. completion: Dec 2011119 patients
Phase 1Completed
NCT07369830Rocket PharmaceuticalsClostridium butyricum

The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function

Start: Oct 2025Est. completion: Jun 2029156 patients
N/ARecruiting
NCT06087718Varian Medical SystemsMaastro applicator

Feasibility of the Maastro Applicator in Rectal Cancer

Start: Aug 2024Est. completion: Apr 2031
N/AActive Not Recruiting
NCT06662643Rocket PharmaceuticalsDelayed transanal pull-through anastomosis

A Clinical Trial Comparing Staged Turnbull-Cutait Pull-through Anastomosis With Direct Anastomosis Plus Prophylactic Ileostomy in the Treatment of Low Rectal Cancer After Internal Sphincter Resection

Start: May 2024Est. completion: Dec 2029110 patients
N/AActive Not Recruiting
NCT05629442GenomicsctDNA

ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer

Start: Jan 2023Est. completion: Jun 203060 patients
N/ANot Yet Recruiting
NCT03828318Providence TherapeuticsPatient Activation Booklet and nursing support for patients with LARS

Impact of a Patient-Centered Program for Low Anterior Resection Syndrome a Multicenter Randomized Controlled Trial

Start: Sep 2019Est. completion: Jan 2024
N/ACompleted
NCT02651701BayerMR-PET

Rectal Cancer Staging Using Whole Body MR-PET

Start: Jan 2016Est. completion: Nov 201971 patients
N/ACompleted

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 2,877 patients
18 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)